Bessemer Group Inc. Sells 23,570 Shares of AtriCure, Inc. $ATRC

Bessemer Group Inc. decreased its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 71.1% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,570 shares of the medical device company’s stock after selling 23,570 shares during the quarter. Bessemer Group Inc.’s holdings in AtriCure were worth $273,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the company. Marshall Wace LLP raised its position in shares of AtriCure by 63.4% during the 4th quarter. Marshall Wace LLP now owns 913,453 shares of the medical device company’s stock valued at $36,136,000 after buying an additional 354,281 shares in the last quarter. Wellington Management Group LLP increased its position in AtriCure by 8.1% during the 3rd quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock valued at $151,296,000 after purchasing an additional 322,818 shares during the period. First Light Asset Management LLC raised its position in shares of AtriCure by 32.0% in the 4th quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company’s stock worth $46,501,000 after acquiring an additional 285,083 shares in the last quarter. Norges Bank acquired a new stake in AtriCure in the fourth quarter valued at approximately $8,466,000. Finally, Oberweis Asset Management Inc. purchased a new stake in shares of AtriCure during the third quarter worth about $5,411,000. 99.11% of the stock is owned by institutional investors.

Insider Transactions at AtriCure

In other news, Director Karen Prange sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $28.65, for a total value of $85,950.00. Following the transaction, the director directly owned 26,373 shares in the company, valued at $755,586.45. This trade represents a 10.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 4.00% of the company’s stock.

AtriCure Stock Performance

NASDAQ ATRC opened at $35.04 on Monday. The company has a market capitalization of $1.77 billion, a P/E ratio of 166.87 and a beta of 1.24. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.29 and a quick ratio of 3.18. AtriCure, Inc. has a 1-year low of $25.36 and a 1-year high of $43.18. The business has a 50 day moving average price of $30.05 and a 200 day moving average price of $31.36.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.37%. The firm had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. During the same period in the prior year, the company earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Sell-side analysts expect that AtriCure, Inc. will post 0.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ATRC. Zacks Research lowered AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 4th. Raymond James Financial set a $52.00 target price on AtriCure in a research note on Tuesday, July 21st. Canaccord Genuity Group increased their target price on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Freedom Capital upgraded shares of AtriCure to a “strong-buy” rating in a report on Wednesday, April 1st. Finally, Wall Street Zen lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $49.12.

AtriCure News Summary

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: Q2 earnings of $0.18 per share beat the $0.03 consensus and improved from a loss a year ago, showing a meaningful profitability turnaround. AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Revenue of $153.6 million topped Wall Street estimates of $151.8 million, reinforcing that demand remains solid. AtriCure Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company lifted FY2026 EPS guidance to $0.24-$0.32, well above the prior consensus, and revenue guidance of $602 million-$610 million is also near or slightly above expectations. AtriCure Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management described the quarter as one of “healthy growth” and a “significant step up in profitability,” which supports the recent stock strength. AtriCure Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Short-interest data showed 0 reported shares, so it does not appear to be a meaningful trading catalyst.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.